Scholarlink

Background <p>H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brainstem tumor with a median overall survival (OS) of less than one year. Radiotherapy (RT) is the standard treatment, but the survival benefit of adding temozolomide (TMZ) remains controversial.</p> Methods <p>Two retrospective cohorts were analyzed. In the single-center cohort (44 patients), patients were divided into three groups: RT alone (<i>n</i> = 16), Stupp regimen (concurrent and adjuvant TMZ, <i>n</i> = 15), and RT followed by sequential TMZ (RT→TMZ, <i>n</i> = 13). In the SEER database cohort (39 patients), patients were divided into RT alone (<i>n</i> = 19) and chemoradiotherapy (CRT, <i>n</i> = 20). Survival was analyzed using the Kaplan-Meier method, log-rank test, and Cox regression.</p> Results <p>In the single-center cohort, no significant differences were observed among the three groups in objective response rate (ORR; <i>P</i> = 0.693), disease control rate (DCR; <i>P</i> = 1.000), median progression-free survival (PFS; 6, 7, and 8 months, respectively; <i>P</i> = 0.621), or median OS (11, 13, and 13 months, respectively; <i>P</i> = 0.534). The Stupp group had significantly higher rates of leukopenia and liver function impairment than the RT group (<i>P</i> &lt; 0.05), with a trend toward more grade ≥ 3 adverse events (AEs). No significant difference in AEs was seen between RT→TMZ and RT. In the SEER cohort, median OS was 11 months in both groups (<i>P</i> = 0.582); median disease-specific survival (DSS) was 11 and 12 months, respectively (<i>P</i> = 0.585).</p> Conclusion <p>Adding TMZ to RT whether (concurrent/adjuvant or sequential) does not significantly improve PFS or OS in H3K27M-mutant DIPG patients. The Stupp regimen significantly increases hematological and hepatic toxicity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of chemoradiotherapy in pediatric H3K27M-mutant diffuse intrinsic pontine glioma: a study based on single-center and SEER data

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月30日

查看全文
  • Dandan Wang,
  • Xiaohao Liu,
  • Juan Wang,
  • Boya Zhang,
  • Suna Zhai,
  • Jiayao Xu,
  • Long Wang,
  • Yingjuan Zheng,
  • Wei Wei,
  • Yubing Zhou

摘要

Background

H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brainstem tumor with a median overall survival (OS) of less than one year. Radiotherapy (RT) is the standard treatment, but the survival benefit of adding temozolomide (TMZ) remains controversial.

Methods

Two retrospective cohorts were analyzed. In the single-center cohort (44 patients), patients were divided into three groups: RT alone (n = 16), Stupp regimen (concurrent and adjuvant TMZ, n = 15), and RT followed by sequential TMZ (RT→TMZ, n = 13). In the SEER database cohort (39 patients), patients were divided into RT alone (n = 19) and chemoradiotherapy (CRT, n = 20). Survival was analyzed using the Kaplan-Meier method, log-rank test, and Cox regression.

Results

In the single-center cohort, no significant differences were observed among the three groups in objective response rate (ORR; P = 0.693), disease control rate (DCR; P = 1.000), median progression-free survival (PFS; 6, 7, and 8 months, respectively; P = 0.621), or median OS (11, 13, and 13 months, respectively; P = 0.534). The Stupp group had significantly higher rates of leukopenia and liver function impairment than the RT group (P < 0.05), with a trend toward more grade ≥ 3 adverse events (AEs). No significant difference in AEs was seen between RT→TMZ and RT. In the SEER cohort, median OS was 11 months in both groups (P = 0.582); median disease-specific survival (DSS) was 11 and 12 months, respectively (P = 0.585).

Conclusion

Adding TMZ to RT whether (concurrent/adjuvant or sequential) does not significantly improve PFS or OS in H3K27M-mutant DIPG patients. The Stupp regimen significantly increases hematological and hepatic toxicity.